Bone Cancer

P=N/A, N=54, Completed, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2025 | Trial primary completion date: Dec 2026 --> Jul 2025

Importantly, co-treatments exhibited greater inhibition of tumor growth than single treatments in cell line- and patient-derived xenograft models. Taken together, our data revealed that THZ1 or TG02 enhanced in vitro and in vivo efficacy of afatinib, suggesting a potential novel combination therapeutic strategy for patients with chordoma.

The patient remained well, without local recurrence or metastasis during 6 years of follow-up. The present tumor highlights the rarity of the location, and the diagnostic challenges encountered prior to surgery.

The prototypic EPRS inhibitor halofuginone demonstrated significant tumour growth inhibition in an in vivo patient-derived xenograft model. These results suggest that targeting metabolic stress pathways via ATF4 activation presents a novel therapeutic approach for chordoma, warranting further clinical investigation.

P=N/A, N=188, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=300 --> 188

Systemic agents such as denosumab or bisphosphonates remain investigational, and radiotherapy is generally contraindicated due to malignant transformation risk...Awareness of risk factors, early imaging-based detection, and complete surgical excision are critical for optimal outcomes. Further multicenter studies are required to define surveillance protocols, validate molecular predictors, and clarify the role of systemic therapy in this challenging condition.

CD3L1 is expressed in osteosarcoma and chordoma and is associated with features of the tumor immune microenvironment, including markers of macrophage infiltration. As a potential therapeutic target, CD3L1 warrants further functional and clinical investigation.

This study provides a foundation for characterizing SBC through QSM, enabling indirect, non-invasive identification of potentially hypoxic tumor regions. Further histological validation with specific hypoxia markers, such as HIF-1α, is nevertheless required.

The results suggest the potential participation of PD-1, PD-L1, and PD-L2 in the pathogenesis of CGCG, PGCG, and GCTB. The locally aggressive behavior of GCTB could be associated with a higher osteoclastogenic and immunosuppressive microenvironment in these neoplasms.

P=N/A, N=800, Recruiting, University of Calgary

Serum calcium and parathyroid hormone measurements are essential in the evaluation of bone lesions. Hypercalcemia may indicate primary hyperparathyroidism but can also occur in myeloma, metastases, or granulomatous diseases.Brown tumours (BTs) and giant cell tumours (GCTs) of bone may overlap; BTs are associated with hypercalcemia and H3F3A negativity, while GCTs are characterized by normal calcium levels and H3F3A positivity.A multidisciplinary approach combining clinical, biochemical, and pathological data improves diagnostic accuracy in bone lesions by distinguishing benign, malignant and metabolic causes, ensuring appropriate management.

Sampling revealed a HMGA2::NCOR2 fusion associated with a recently described subset of giant cell-rich bone and soft tissue tumors. This case expands the differential diagnosis for cross-physeal and epiphyseal bone tumors in pediatric patients and highlights the radiological features of keratin-positive giant cell-rich tumor (KPGCT).